Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV. Ellen Maher, Richard Pazdur, Laura L. Fernandes et al.|Journal of Clinical Oncology|2019Cited by 348
FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E MutationGeoffrey Kim, Richard Pazdur, Kun He et al.|Clinical Cancer Research|2014Cited by 215
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing ChemotherapyDaniel L. Suzman, Julia A. Beaver, Sundeep Agrawal et al.|The Oncologist|2018Cited by 200
Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval SummaryYang‐Min Ning, Richard Pazdur, William F. Pierce et al.|Clinical Cancer Research|2013Cited by 67
Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval SummaryPaul G. Kluetz, Richard Pazdur, Yang‐Min Ning et al.|Clinical Cancer Research|2013Cited by 62